Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea

Secretory diarrhea has a significant impact on morbidity and mortality worldwide and may be a predominant or minor component of pathogenesis in diarrhea of various etiologies. Crofelemer is a first-in-class antidiarrheal medication with unique inhibitory mechanisms at both the cystic fibrosis transm...

Full description

Saved in:
Bibliographic Details
Published inDrugs of today (Barcelona, Spain : 1998) Vol. 49; no. 4; p. 239
Main Authors Yeo, Q M, Crutchley, R, Cottreau, J, Tucker, A, Garey, K W
Format Journal Article
LanguageEnglish
Published Spain 01.04.2013
Subjects
Animals
Antidiarrheals - adverse effects
Antidiarrheals - pharmacology
Antidiarrheals - therapeutic use
Diarrhea - drug therapy
Diarrhea - virology
Drug Interactions
HIV Infections - complications
Humans
Proanthocyanidins - adverse effects
Proanthocyanidins - pharmacology
Proanthocyanidins - therapeutic use
HIV/AIDS
Diarrhea
Crofelemer
Cholera
CFTR gene
Clostridium difficile
Online AccessGet more information

Cover

More Information
Summary:Secretory diarrhea has a significant impact on morbidity and mortality worldwide and may be a predominant or minor component of pathogenesis in diarrhea of various etiologies. Crofelemer is a first-in-class antidiarrheal medication with unique inhibitory mechanisms at both the cystic fibrosis transmembrane conductance regulator and the calcium-activated chloride channels which are responsible for chloride secretion and subsequent luminal hydration. The efficacy of crofelemer has been investigated in patients with HIV-associated diarrhea, diarrhea of various infectious etiologies, as well as diarrhea-predominant irritable bowel syndrome. Crofelemer was approved by the FDA in December 2012 to treat diarrhea in HIV/AIDS patients on antiretroviral therapy. Crofelemer is not absorbed in the body and well-tolerated in small trials performed to date although long-term safety data is lacking. Crofelemer may be an important addition to the currently available drugs for the management of secretory diarrhea.
ISSN:1699-3993
DOI:10.1358/dot.2013.49.4.1947253